Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 8.


Psarelli, EE ORCID: 0000-0002-3102-0288, Jackson, R, Neoptolemos, JP, Palmer, DH ORCID: 0000-0002-7147-5703, Ghaneh, P, Halloran, CM ORCID: 0000-0002-5471-4178 and Buechler, MW
(2017) Beyond ESPAC-4: better surgery and systemic therapy. LANCET, 389 (10078). pp. 1517-1518.


Neoptolemos, JP, Palmer, DH ORCID: 0000-0002-7147-5703, Ghaneh, P, Psarelli, EE ORCID: 0000-0002-3102-0288, Valle, JW, Halloran, CM ORCID: 0000-0002-5471-4178, Faluyi, O, O'Reilly, DA, Cunningham, D, Wadsley, J
et al (show 24 more authors) (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet (London, England), 389 (10073). pp. 1011-1024.


Neoptolemos, JP, Palmer, DH ORCID: 0000-0002-7147-5703, Ghaneh, P, Psarelli, EE ORCID: 0000-0002-3102-0288, Valle, JW, Halloran, CM ORCID: 0000-0002-5471-4178, Faluyi, O, O'Reilly, DA, Cunningham, D, Wadsley, J
et al (show 24 more authors) (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet (London, England), 389 (10073). 1011 - 1024.


Griffin, R ORCID: 0000-0003-4521-948X, Psarelli, EE ORCID: 0000-0002-3102-0288, Cox, TF, Khedr, M ORCID: 0000-0002-4998-2397, Milan, AM ORCID: 0000-0002-0452-2338, Davison, AS ORCID: 0000-0001-5501-4475, Hughes, AT, Usher, JL, Taylor, S, Loftus, N
et al (show 17 more authors) (2018) Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone. Data in Brief, 20. pp. 1620-1628.


Jackson, R, Psarelli, EE ORCID: 0000-0002-3102-0288, Berhane, S, Khan, H and Johnson, PJ ORCID: 0000-0003-1404-0209
(2017) Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials. Journal of Clinical Oncology, 35 (6). pp. 622-628.


Ranganath, LR, Khedr, M ORCID: 0000-0002-4998-2397, Milan, AM ORCID: 0000-0002-0452-2338, Davison, AS ORCID: 0000-0001-5501-4475, Hughes, AT, Usher, JL, Taylor, S, Loftus, N, Daroszewska, A ORCID: 0000-0002-6692-6610, West, E
et al (show 17 more authors) (2018) Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre. Molecular genetics and metabolism, 125 (1-2). pp. 127-134.


Milan, AM ORCID: 0000-0002-0452-2338, Hughes, AT, Davison, AS ORCID: 0000-0001-5501-4475, Khedr, M ORCID: 0000-0002-4998-2397, Rovensky, J, Psarelli, EE ORCID: 0000-0002-3102-0288, Cox, TF, Rhodes, NP ORCID: 0000-0002-5173-7032, Gallagher, JA and Ranganath, LR
(2019) Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria. SCIENTIFIC REPORTS, 9 (1). 10024-.


Cox, T, Psarelli, EE ORCID: 0000-0002-3102-0288, Taylor, S, Shepherd, HR, Robinson, M, Barton, G, Mistry, A, Genovese, F, Braconi, D, Giustarini, D
et al (show 12 more authors) (2019) Subclinical ochronosis features in alkaptonuria: A cross-sectional study. BMJ Innovations, 5 (2-3). pp. 82-91.

This list was generated on Sat Feb 24 08:40:51 2024 GMT.